Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $177.67 million. The enterprise value is $32.65 million.
Important Dates
The next estimated earnings date is Wednesday, March 4, 2026, before market open.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 97.62 million shares outstanding. The number of shares has increased by 3.57% in one year.
| Current Share Class | 97.62M |
| Shares Outstanding | 97.62M |
| Shares Change (YoY) | +3.57% |
| Shares Change (QoQ) | +6.73% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 46.76% |
| Float | 97.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.05 |
| Forward PS | 16.59 |
| PB Ratio | 11.54 |
| P/TBV Ratio | 13.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of 1.46.
| Current Ratio | 2.86 |
| Quick Ratio | 2.81 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.04 |
Financial Efficiency
Return on equity (ROE) is -211.37% and return on invested capital (ROIC) is -60.51%.
| Return on Equity (ROE) | -211.37% |
| Return on Assets (ROA) | -28.26% |
| Return on Invested Capital (ROIC) | -60.51% |
| Return on Capital Employed (ROCE) | -85.50% |
| Weighted Average Cost of Capital (WACC) | 17.33% |
| Revenue Per Employee | $188,549 |
| Profits Per Employee | -$812,337 |
| Employee Count | 246 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.85% in the last 52 weeks. The beta is 2.19, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.19 |
| 52-Week Price Change | +32.85% |
| 50-Day Moving Average | 2.20 |
| 200-Day Moving Average | 2.49 |
| Relative Strength Index (RSI) | 39.62 |
| Average Volume (20 Days) | 1,829,676 |
Short Selling Information
The latest short interest is 11.83 million, so 12.12% of the outstanding shares have been sold short.
| Short Interest | 11.83M |
| Short Previous Month | 11.32M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 12.16% |
| Short Ratio (days to cover) | 6.38 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $46.38 million and -$199.84 million in losses. Loss per share was -$2.35.
| Revenue | 46.38M |
| Gross Profit | -64.78M |
| Operating Income | -119.68M |
| Pretax Income | -199.84M |
| Net Income | -199.84M |
| EBITDA | -112.04M |
| EBIT | -119.68M |
| Loss Per Share | -$2.35 |
Full Income StatementBalance Sheet
The company has $165.65 million in cash and $19.65 million in debt, with a net cash position of $146.00 million or $1.50 per share.
| Cash & Cash Equivalents | 165.65M |
| Total Debt | 19.65M |
| Net Cash | 146.00M |
| Net Cash Per Share | $1.50 |
| Equity (Book Value) | 13.45M |
| Book Value Per Share | 0.14 |
| Working Capital | 115.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$179.62 million and capital expenditures -$1.09 million, giving a free cash flow of -$180.70 million.
| Operating Cash Flow | -179.62M |
| Capital Expenditures | -1.09M |
| Free Cash Flow | -180.70M |
| FCF Per Share | -$1.85 |
Full Cash Flow StatementMargins
| Gross Margin | -139.66% |
| Operating Margin | -258.03% |
| Pretax Margin | -430.84% |
| Profit Margin | n/a |
| EBITDA Margin | -241.55% |
| EBIT Margin | -258.03% |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.57% |
| Shareholder Yield | -3.57% |
| Earnings Yield | -111.86% |
| FCF Yield | -101.15% |
Analyst Forecast
The average price target for Editas Medicine is $4.50, which is 147.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 147.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -2.00% |
| EPS Growth Forecast (5Y) | -15.84% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -11.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.73 |
| Piotroski F-Score | 3 |
